Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021041964 - CONJUGATED INHIBITORS OF DNA DAMAGE RESPONSE

Publication Number WO/2021/041964
Publication Date 04.03.2021
International Application No. PCT/US2020/048608
International Filing Date 28.08.2020
IPC
A61K 31/4178 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4168 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4168having a nitrogen atom attached in position 2, e.g. clonidine
A61K 31/473 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
CPC
A61K 47/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • PROLYNX LLC [US]/[US]
Inventors
  • FONTAINE, Shaun, D.
  • HEARN, Brian, R.
  • SANTI, Daniel, V.
Agents
  • HUANG, Huang
  • MULLEN III, James J.
  • AHN, Sejin
  • CASALE, Amanda
  • CHAN, Ngam, Fung David
  • ESCAJADILLO, Tamara
  • O'SULLIVAN, Desmond
  • POTTER, Karen
  • RICE, Rachel
  • SCHMIDT, Jeffrey W.
  • YIN, Bu
Priority Data
62/893,07528.08.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CONJUGATED INHIBITORS OF DNA DAMAGE RESPONSE
(FR) INHIBITEURS CONJUGUÉS DE LA RÉPONSE À L'ENDOMMAGEMENT DE L'ADN
Abstract
(EN)
Provided herein are releasable conjugates of inhibitors of DNA damage response suitable for use as therapeutic agents in the treatment of disease.
(FR)
L'invention concerne des conjugués libérables d'Inhibiteurs de la réponse à l'endommagement de l'ADN appropriés pour une utilisation en tant qu'agents thérapeutiques dans le traitement d'une maladie.
Latest bibliographic data on file with the International Bureau